Prospects and Challenges of CAR-T Cell Therapy Combined with ICIs

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Apr 4

PMID 38571495

Authors

Yufan Lv

Xinyu Luo

Zhuoyi Xie

Jieya Qiu

Jinsai Yang

Yuqi Deng

Rou Long

Guiyang Tang

Chaohui Zhang

Jianhong Zuo

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology. Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.

Citing Articles

Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors.

Jaing T, Hsiao Y, Wang Y Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996811 PMC: 11854309. DOI: 10.3390/cimb47020090.

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Passariello M, Manna L, Rapuano Lembo R, Yoshioka A, Inoue T, Kajiwara K Cell Death Discov. 2025; 11(1):58.

PMID: 39929828 PMC: 11811032. DOI: 10.1038/s41420-025-02329-8.

From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma.

Fotiou D, Katodritou E J Clin Med. 2025; 14(2.

PMID: 39860333 PMC: 11765558. DOI: 10.3390/jcm14020327.

Advances in Cell and Immune Therapies for Melanoma.

Timis T, Buruiana S, Dima D, Nistor M, Muresan X, Cenariu D Biomedicines. 2025; 13(1).

PMID: 39857682 PMC: 11761552. DOI: 10.3390/biomedicines13010098.

References

Hay K, Gauthier J, Hirayama A, Voutsinas J, Wu Q, Li D . Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019; 133(15):1652-1663. PMC: 6460418. DOI: 10.1182/blood-2018-11-883710. View

Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M . Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1 T lymphocyte niches through a feed-forward loop. Cancer Cell. 2022; 40(12):1600-1618.e10. PMC: 9899876. DOI: 10.1016/j.ccell.2022.11.002. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

DuFort C, DelGiorno K, Hingorani S . Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2016; 150(7):1545-1557.e2. PMC: 4957812. DOI: 10.1053/j.gastro.2016.03.040. View

Zhu H, You Y, Shen Z, Shi L . EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity. Pathol Oncol Res. 2020; 26(4):2135-2141. DOI: 10.1007/s12253-019-00759-1. View

Li H, Huang Y, Jiang D, Cui L, He Z, Wang C . Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis. 2018; 9(2):177. PMC: 5833445. DOI: 10.1038/s41419-017-0238-6. View

Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C . PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019; 7(1):209. PMC: 6686487. DOI: 10.1186/s40425-019-0685-y. View

Ostrand-Rosenberg S, Sinha P, Beury D, Clements V . Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012; 22(4):275-81. PMC: 3701942. DOI: 10.1016/j.semcancer.2012.01.011. View

10.

Kodumudi K, Siegel J, Weber A, Scott E, Sarnaik A, Pilon-Thomas S . Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy. PLoS One. 2016; 11(4):e0153053. PMC: 4822778. DOI: 10.1371/journal.pone.0153053. View

11.

Hamilton A, Swingle K, Joseph R, Mai D, Gong N, Billingsley M . Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering. Adv Healthc Mater. 2023; 12(30):e2301515. DOI: 10.1002/adhm.202301515. View

12.

Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R . Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Cancer Res. 2021; 81(11):3022-3035. DOI: 10.1158/0008-5472.CAN-20-2701. View

13.

Yamaguchi Y, Gibson J, Ou K, Lopez L, Ng R, Leggett N . PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. J Immunother Cancer. 2022; 10(6). PMC: 9226933. DOI: 10.1136/jitc-2021-004400. View

14.

Mognol G, Spreafico R, Wong V, Scott-Browne J, Togher S, Hoffmann A . Exhaustion-associated regulatory regions in CD8 tumor-infiltrating T cells. Proc Natl Acad Sci U S A. 2017; 114(13):E2776-E2785. PMC: 5380094. DOI: 10.1073/pnas.1620498114. View

15.

Henke E, Nandigama R, Ergun S . Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Front Mol Biosci. 2020; 6:160. PMC: 7025524. DOI: 10.3389/fmolb.2019.00160. View

16.

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

17.

Chalise L, Kato A, Ohno M, Maeda S, Yamamichi A, Kuramitsu S . Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma. Mol Ther Oncolytics. 2022; 26:265-274. PMC: 9364057. DOI: 10.1016/j.omto.2022.07.006. View

18.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

19.

Chamoto K, Al-Habsi M, Honjo T . Role of PD-1 in Immunity and Diseases. Curr Top Microbiol Immunol. 2017; 410:75-97. DOI: 10.1007/82_2017_67. View

20.

Park J, Cheung N . Promise and Challenges of T Cell Immunotherapy for Osteosarcoma. Int J Mol Sci. 2023; 24(15). PMC: 10419531. DOI: 10.3390/ijms241512520. View